Exelixis gains after cancer drug meets late-stage trial goal

Exelixis

21/08/2023 14:10

** Exelixis'  EXEL.O  shares rise 1.7% to $21.45 premarket
    ** Co's cancer therapy, Cabometyx, in combination with
Roche's  ROG.S  antibody treatment Tecentriq, helped extend the
time patients with a type of prostate cancer lived without their
disease worsening
    ** EXEL and partner Ipsen  IPN.PA  say data on overall
survival, another main goal of the trial, is not yet ready for
analysis 
    ** According to the Center for Disease Control, prostate
cancer is the second most common cancer among men in the U.S.
    ** Cabometyx is already approved for treating other types of
cancer including kidney and thyroid cancer 
    ** Up to last close shares up 31.6% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))